MCID: END035
MIFTS: 57

Endocrine Gland Cancer

Categories: Cancer diseases, Endocrine diseases

Aliases & Classifications for Endocrine Gland Cancer

MalaCards integrated aliases for Endocrine Gland Cancer:

Name: Endocrine Gland Cancer 12 15
Endocrine Neoplasm 12 56 17
Malignant Neoplasm of Endocrine Gland 12 74
Endocrine Gland Neoplasms 45 74
Malignant Tumour of Endocrine Gland 12
Neoplasm of the Endocrine System 30
Neoplasm of Endocrine System 12
Carcinoma of Endocrine Gland 74
Neoplasm of Endocrine Gland 12
Malignant Endocrine Tumor 12
Endocrine Tumor 12

Classifications:



External Ids:

Disease Ontology 12 DOID:170
ICD9CM 36 194.9
MeSH 45 D004701
NCIt 51 C3010 C3575
SNOMED-CT 69 93780007
ICD10 34 C75.9

Summaries for Endocrine Gland Cancer

Disease Ontology : 12 An organ system cancer located in endocrine system that is characterized by uncontrolled cellular proliferation of the hormone producing glands of the endocrine system.

MalaCards based summary : Endocrine Gland Cancer, also known as endocrine neoplasm, is related to non-functioning pancreatic endocrine tumor and islet cell tumor. An important gene associated with Endocrine Gland Cancer is SYP (Synaptophysin), and among its related pathways/superpathways are Pathways in cancer and Glioma. The drugs Iodine and Pancrelipase have been mentioned in the context of this disorder. Affiliated tissues include thyroid, pancreas and breast, and related phenotypes are homeostasis/metabolism and endocrine/exocrine gland

Related Diseases for Endocrine Gland Cancer

Diseases related to Endocrine Gland Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 239)
# Related Disease Score Top Affiliating Genes
1 non-functioning pancreatic endocrine tumor 34.3 CHGA GAST SYP
2 islet cell tumor 33.0 CHGA GAST IAPP SST VIP
3 wdha syndrome 32.9 SST VIP
4 insulinoma 32.9 CHGA GCG IAPP SST
5 multiple endocrine neoplasia, type i 32.9 CHGA GAST GNAS RET SST SYP
6 neuroendocrine tumor 32.6 CHGA GAST SST SYP
7 vipoma 32.4 CHGA GAST SST VIP
8 pancreatic cholera 32.4 GAST GCG SST VIP
9 pancreatic cancer 32.4 BRCA1 BRCA2 GAST KDR SST TP53
10 thyroid cancer 31.0 CHGA GNAS KDR RET SST TG
11 thyroid carcinoma, familial medullary 31.0 CHGA GAST RET SST TG
12 pheochromocytoma 30.7 CHGA RET SST SYP VIP
13 glucagonoma 30.6 CHGA SST VIP
14 carcinoid syndrome 30.6 CHGA SST SYP
15 somatostatinoma 30.6 CHGA SST VIP
16 zollinger-ellison syndrome 30.6 CHGA GAST SST
17 adenoma 30.5 GNAS MLH1 RET SST TP53
18 adenocarcinoma 30.5 GNAS KDR MLH1 RET TP53
19 pancreatoblastoma 30.4 AFP CHGA SST SYP
20 small cell carcinoma 30.4 CHGA SYP TP53
21 merkel cell carcinoma 30.4 CHGA SST SYP TP53
22 gastrinoma 30.4 CHGA GAST SST VIP
23 atrophic gastritis 30.4 CHGA GAST SST TP53
24 pancreatic somatostatinoma 30.3 SST SYP
25 hyperparathyroidism 30.3 CHGA GAST RET
26 primary hyperparathyroidism 30.1 CHGA GAST RET
27 functioning pancreatic endocrine tumor 12.1
28 pancreatic neuroendocrine tumor 11.7
29 carney complex variant 11.5
30 parathyroid carcinoma 11.1
31 adrenal carcinoma 11.1
32 multiple endocrine neoplasia 11.1
33 multiple endocrine neoplasia, type iib 11.1
34 non-functioning neuroendocrine tumor of pancreas 11.1
35 multiple endocrine neoplasia, type iia 11.0
36 carney complex, type 1 11.0
37 pulmonary large cell neuroendocrine carcinoma 10.7 CHGA SYP
38 gallbladder small cell carcinoma 10.7 CHGA SYP
39 chordoid meningioma 10.7 CHGA SYP
40 hypoganglionosis 10.7 RET SYP
41 fibroepithelial basal cell carcinoma 10.7 CHGA TP53
42 goblet cell carcinoid 10.7 CHGA GAST
43 breast-ovarian cancer, familial 1 10.7 BRCA1 BRCA2
44 gastrointestinal neuroendocrine tumor 10.7 CHGA SST SYP
45 meningioma, familial 10.7 SST SYP TP53
46 acinar cell cystadenocarcinoma 10.7 CHGA SERPINA3 SYP
47 ureter small cell carcinoma 10.7 CHGA SYP
48 cellular ependymoma 10.7 CHGA SYP TP53
49 carcinoid tumors, intestinal 10.7 CHGA SST SYP
50 hereditary site-specific ovarian cancer syndrome 10.7 BRCA1 BRCA2

Graphical network of the top 20 diseases related to Endocrine Gland Cancer:



Diseases related to Endocrine Gland Cancer

Symptoms & Phenotypes for Endocrine Gland Cancer

MGI Mouse Phenotypes related to Endocrine Gland Cancer:

47 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.35 ADAM17 AFP BRCA1 BRCA2 CHGA GAST
2 endocrine/exocrine gland MP:0005379 10.29 ADAM17 AFP BRCA1 BRCA2 CHGA GAST
3 immune system MP:0005387 10.27 ADAM17 BRCA1 BRCA2 GAST GNAS IAPP
4 mortality/aging MP:0010768 10.22 ADAM17 AFP BRCA1 BRCA2 CHGA GAST
5 hematopoietic system MP:0005397 10.19 ADAM17 BRCA1 BRCA2 GNAS IAPP KDR
6 digestive/alimentary MP:0005381 10.18 ADAM17 BRCA1 BRCA2 GAST MLH1 RET
7 nervous system MP:0003631 10.06 ADAM17 BRCA1 BRCA2 CHGA GNAS KDR
8 limbs/digits/tail MP:0005371 9.98 ADAM17 BRCA1 BRCA2 GNAS RET TG
9 neoplasm MP:0002006 9.97 AFP BRCA1 BRCA2 GAST GNAS MLH1
10 normal MP:0002873 9.96 ADAM17 BRCA1 BRCA2 GNAS KDR RET
11 reproductive system MP:0005389 9.81 ADAM17 AFP BRCA1 BRCA2 CHGA MLH1
12 respiratory system MP:0005388 9.56 ADAM17 BRCA1 GNAS KDR MLH1 RET
13 skeleton MP:0005390 9.28 ADAM17 BRCA1 BRCA2 GNAS IAPP KDR

Drugs & Therapeutics for Endocrine Gland Cancer

Drugs for Endocrine Gland Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1025)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Iodine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 7553-56-2 807
2
Pancrelipase Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 53608-75-6
3
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 38904 10339178 498142
4
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 33069-62-4 36314
5
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 216974-75-3
6
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-23-7 5754
7
Hydrocortisone acetate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-03-3
8
Dexmedetomidine Approved, Vet_approved Phase 4,Not Applicable 113775-47-6 68602 5311068
9
Celecoxib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 169590-42-5 2662
10
Prednisone Approved, Vet_approved Phase 4,Phase 2 53-03-2 5865
11
Sevoflurane Approved, Vet_approved Phase 4,Not Applicable 28523-86-6 5206
12
Sodium Citrate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 68-04-2
13
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable 437-38-7 3345
14
Parathyroid hormone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 9002-64-6
15
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 441203 84093 2767
16
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 50-02-2 5743
17
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 1177-87-3
18
Tranexamic Acid Approved Phase 4,Phase 2,Phase 3 1197-18-8 5526
19
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 23214-92-8 31703
20
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable 2078-54-8 4943
21
Ibuprofen Approved Phase 4,Not Applicable 15687-27-1 3672
22
Morphine Approved, Investigational Phase 4,Not Applicable 57-27-2 5288826
23
Oxycodone Approved, Illicit, Investigational Phase 4,Not Applicable 76-42-6 5284603
24
Iron Approved, Experimental Phase 4,Phase 2,Not Applicable 7439-89-6, 15438-31-0 23925 27284
25
Somatostatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 38916-34-6, 51110-01-1 53481605
26
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 657-24-9 14219 4091
27
Ethanol Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 64-17-5 702
28
Sunitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 557795-19-4, 341031-54-7 5329102
29
Octreotide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 83150-76-9 6400441 383414
30
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 62-31-7, 51-61-6 681
31
Tramadol Approved, Investigational Phase 4,Not Applicable 27203-92-5 33741
32
Codeine Approved, Illicit Phase 4,Not Applicable 76-57-3 5284371
33
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 95058-81-4 60750
34
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-05-9 6006 143
35
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
36
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53123-88-9 46835353 6436030 5284616
37
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 159351-69-6 6442177 70789204
38
Desflurane Approved Phase 4,Not Applicable 57041-67-5 42113
39
Olaparib Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 763113-22-0 23725625
40
Ferrous fumarate Approved Phase 4,Early Phase 1 141-01-5
41
Pembrolizumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 1374853-91-4
42
Lenvatinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 417716-92-8
43
Niraparib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 1038915-60-4 24958200
44
Dexlansoprazole Approved, Investigational Phase 4 138530-94-6, 103577-45-3 9578005
45
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
46
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 1,Not Applicable 439-14-5 3016
47
Cinacalcet Approved Phase 4,Phase 3 226256-56-0 156419
48
Rocuronium Approved Phase 4,Phase 3,Not Applicable 119302-91-9, 143558-00-3 441290
49
Etomidate Approved Phase 4,Phase 3,Phase 1,Phase 2 33125-97-2 36339 667484
50
Meperidine Approved Phase 4 57-42-1 4058

Interventional clinical trials:

(show top 50) (show all 4754)
# Name Status NCT ID Phase Drugs
1 Clinical Effectiveness of Serum Chromogranin A Levels on Diagnostic of Pancreatic Neuroendocrine Tumors Unknown status NCT02759718 Phase 4
2 rAd-p53 Gene Therapy for Advanced Malignant Thyroid Tumors Unknown status NCT00902122 Phase 4 rAd-p53 gene;p53 gene therapy
3 Total Thyroidectomy With Harmonic Scalpel® Unknown status NCT00385983 Phase 4
4 Evaluation of EUS-Guided 22 Gauge Core Biopsy Versus Fine-needle Aspiration for Suspected Pancreatic Neoplasms Unknown status NCT01673334 Phase 4
5 Study of Clinical and Biological Prognostic Factors in Patients With Ovarian Cancer Receiving Carboplatin +Paclitaxel With Bevacizumab Unknown status NCT01706120 Phase 4 Bevacizumab;Paclitaxel;Carboplatin
6 Radiolabeled Molecules for Medullary Thyroid Cancer Unknown status NCT01915485 Phase 4
7 Additional Effects of Perioperative Immunonutrition in Patients Undergoing Pancreaticoduodenectomy Unknown status NCT01969110 Phase 4
8 Effect of Dexmedetomidine on Plasmatic Cortisol Response in Transsphenoidal Surgery Unknown status NCT02549768 Phase 4 Dexmedetomidine;Sodium Chloride 0.9%
9 Cyclooxygenase-2 Inhibitor for Adjuvant Anticancer Effect in Patients With Biliary-pancreas Cancer Unknown status NCT01111591 Phase 4 Cox2 inhibitor (Celecoxib)
10 Effect of Perioperative Glucocorticoid Replacement on Prognosis of Surgical Patients With Sellar Lesions Unknown status NCT02190994 Phase 4 Hydrocortisone;Prednisone
11 Parenteral Fish Oil in Major Laparoscopic Abdominal Surgery Unknown status NCT01819961 Phase 4 MCT/LCT and fish oil;MCT/LCT
12 Treatment of Zollinger-Ellison Syndrome With Prevacid Completed NCT00204373 Phase 4 Lansoprazole (Prevacid)
13 Quality of Life, Recombinant TSH (Thyrogen) and Thyroid Cancer Completed NCT00604318 Phase 4 rhTSH
14 Study of Radioiodine (131-I) Uptake Following Administration of Thyrogen and Hypothyroid States During Thyroid Hormone Withdrawal. Completed NCT00001730 Phase 4 Thyrogen
15 Dose-dependent Effect of Fentanyl on Cough Attenuation During Emergence From General Anaesthesia Completed NCT01308320 Phase 4 fentanyl citrate;saline
16 RCT: Difference in Diagnostic Yield Between EUSFNA Needles With and Without a Side Port in Pancreatic Masses Completed NCT02092519 Phase 4
17 Percutaneous Laser Ablation in Benign Thyroid Nodules.Long Term Results Completed NCT00858104 Phase 4
18 A Study of an Investigational Medication for Severe Primary Hyperparathyroidism or Parathyroid Cancer Completed NCT00037518 Phase 4 AMG 073
19 Taste, Smell and Chemotherapy (TASTY) Completed NCT01641172 Phase 4
20 Tumor Gene Expression in Women With Ovarian Cancer Completed NCT00817479 Phase 4 Dexamethasone;Placebo
21 Tranexamic Acid in Surgery of Advanced Ovarian Cancer Completed NCT00740116 Phase 4 Tranexamic acid;0.9% NaCl solution
22 A Study to Evaluate Efficacy and Tolerance of Caelyx in Patients With Epithelial Ovarian Cancer. (Study P04072)(COMPLETED) Completed NCT00727961 Phase 4 Pegylated Liposomal Doxorubicin hydrochloride
23 The Importance of Albumin Infusion Rate for Plasma Volume Expansion Following Major Abdominal Surgery Completed NCT02728921 Phase 4 5% Albumin infusion 30 min;5% Albumin infusion 3 hours
24 Is the Routine Pressure Dressing After Thyroidectomy Necessary? Completed NCT00400465 Phase 4
25 Pre-operative Biliary SEMS RCT During Neoadjuvant Therapy Completed NCT02238847 Phase 4
26 Effects of Dexmedetomidine During IRE Procedures for Solid Tumours Completed NCT02044224 Phase 4 Dexmedetomidine
27 Etomidate vs. Midazolam for Sedation During ERCP Completed NCT02027311 Phase 4 Etomidate;Midazolam;Meperidine
28 RCT Steel (Wallstent®) vs Nitinol (Wallflex®) Bile Duct Stent for Palliation of Malignant Obstruction Completed NCT00980889 Phase 4
29 Protexa® Versus TiLoopBra® in Immediate Breast Reconstruction- A Pilot Study Completed NCT02562170 Phase 4
30 The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. Completed NCT03384511 Phase 4 Apatinib
31 Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment Completed NCT03080181 Phase 4 Pasireotide 0.6 MG/ML
32 Effects of Preoperative Immunonutrition in Patients Undergoing Pancreaticoduodenectomy Completed NCT01256034 Phase 4
33 Analgesia Regimens Following Trans-sphenoidal Surgery for Pituitary Tumors Completed NCT02351700 Phase 4 IV Caldolor (IV Ibuprofen);IV Ibuprofen placebo
34 Comparing Covered Self-expandable Metallic Stent (SEMS) Above/Across the Sphincter of Oddi Completed NCT01041612 Phase 4
35 Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients Completed NCT00966277 Phase 4 Dalteparin
36 Pre-Operative Staging of Pancreatic Cancer Using Superparamagnetic Iron Oxide Magnetic Resonance Imaging (SPIO MRI) Completed NCT00920023 Phase 4 Superparamagnetic Iron Oxide Magnetic Resonance Imaging
37 Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly Completed NCT02060383 Phase 4 Pasireotide s.c.;Sitagliptin;Liraglutide;Insulin;Pasireotide LAR;Metformin
38 Randomized Clinical Trial of Posterior Retroperitoneoscopic Adrenalectomy Versus Lateral Laparoscopic Adrenalectomy Completed NCT01959711 Phase 4
39 Prospective Study of Celiac Block Injection: 1 vs. 2 Completed NCT00583479 Phase 4
40 Endoscopic Ultrasound-guided Celiac Plexus Neurolysis (EUS-CPN)With Alcohol in Unresectable Pancreatic Cancer: a Pilot Study Completed NCT00578279 Phase 4 dehydrated alcohol
41 Standard and Immunostimulating Enteral Nutrition in Surgical Patients Completed NCT00576940 Phase 4 Reconvan;Peptisorb
42 The Impact of Immunostimulating Nutrition on the Outcome of Surgery Completed NCT00558155 Phase 4 peptisorb;Stresson;Parenteral nutrition;Omegaven, Dipeptiven
43 A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors Completed NCT01525550 Phase 4 sunitinib
44 Biliary Metal Stent Study: Metal Stents for Management of Distal Malignant Biliary Obstruction Completed NCT00280709 Phase 4
45 Surgical Debulking of Pituitary Adenomas Completed NCT01371643 Phase 4 Octreotide LAR
46 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed NCT00666978 Phase 4 bupropion hydrochloride
47 Preoperative Octreotide Treatment of Acromegaly Completed NCT00521300 Phase 4 Octreotide
48 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
49 A Study to Evaluate the Safety and Efficacy of Lenvatinib in Participants With Refractory Differentiated Thyroid Cancer Recruiting NCT03573960 Phase 4 Lenvatinib
50 Levothyroxine Replacement With Liquid Gel Capsules vs Tablets Post-thyroidectomy Recruiting NCT02946918 Phase 4 Levothyroxine

Search NIH Clinical Center for Endocrine Gland Cancer

Cochrane evidence based reviews: endocrine gland neoplasms

Genetic Tests for Endocrine Gland Cancer

Genetic tests related to Endocrine Gland Cancer:

# Genetic test Affiliating Genes
1 Neoplasm of the Endocrine System 30

Anatomical Context for Endocrine Gland Cancer

MalaCards organs/tissues related to Endocrine Gland Cancer:

42
Thyroid, Pancreas, Breast, Pituitary, T Cells, Testes, Liver

The Foundational Model of Anatomy Ontology organs/tissues related to Endocrine Gland Cancer:

20
Endocrine System

Publications for Endocrine Gland Cancer

Articles related to Endocrine Gland Cancer:

(show all 39)
# Title Authors Year
1
Clinical trial enrollment in patients with endocrine neoplasm: Parity achievable, but cancer. ( 30862353 )
2019
2
Parathyroid carcinoma in multiple endocrine neoplasm type 1 syndrome: case report and systematic literature review. ( 29922966 )
2018
3
Educational Case: Endocrine Neoplasm: Medullary Thyroid Carcinoma. ( 29978018 )
2018
4
Unusual gastric subepithelial tumor: primary mixed acinar-endocrine neoplasm in an anemic woman. ( 29102730 )
2018
5
Pancreatic Endocrine Neoplasm Concomitant with a Complicated Endocrine History: A Case Report and Literature Review. ( 30631835 )
2017
6
Solid pseudopapillary neoplasm collides with a well-differentiated pancreatic endocrine neoplasm in an adult man: case report and review of histogenesis. ( 25596255 )
2015
7
Lipid-rich variant of a pancreatic endocrine neoplasm in an endoscopic ultrasound-guided fine needle aspiration biopsy. ( 22549971 )
2013
8
Concomitant pancreatic endocrine neoplasm and intraductal papillary mucinous neoplasm: a case report and literature review. ( 23517520 )
2013
9
Proposed histopathologic grading system derived from a study of KIT and CK19 expression in pancreatic endocrine neoplasm. ( 21190722 )
2011
10
Coincidence of GIST and pancreatic endocrine neoplasm in neurofibromatosis. ( 21884431 )
2011
11
Tumor-to-tumor metastasis: report of a case of renal cell carcinoma metastasizing to a pancreatic endocrine neoplasm. ( 21245422 )
2011
12
Role of RET codonic mutations in the surgical management of medullary thyroid carcinoma in pediatric age multiple endocrine neoplasm type 2 syndromes. ( 20713208 )
2010
13
E-cadherin/beta-catenin and CD10: a limited immunohistochemical panel to distinguish pancreatic endocrine neoplasm from solid pseudopapillary neoplasm of the pancreas on endoscopic ultrasound-guided fine-needle aspirates of the pancreas. ( 19926573 )
2009
14
Endoscopic ultrasound-guided fine-needle aspiration diagnosis of clear-cell pancreatic endocrine neoplasm in a patient with von Hippel-Lindau disease: a case report. ( 19217049 )
2009
15
Image of the month. Low-grade, nonfunctioning cystic pancreatic endocrine neoplasm. ( 19153332 )
2009
16
Cystic nonfunctioning pancreatic endocrine neoplasm presenting communication with main pancreatic duct. ( 19153491 )
2009
17
Nonfunctioning pancreatic endocrine neoplasm presenting as asymptomatic, isolated pancreatic duct stricture: a case report and review of the literature. ( 18306872 )
2008
18
Combined serous cystadenoma and pancreatic endocrine neoplasm. A case report with a brief review of the literature. ( 17625299 )
2007
19
Intraductal spread by metastatic islet cell tumor (well-differentiated pancreatic endocrine neoplasm) involving the breast of a child, mimicking a primary mammary carcinoma. ( 16819337 )
2006
20
Endocrine neoplasm scintigraphy: added value of fusing SPECT/CT images compared with traditional side-by-side analysis. ( 17053381 )
2006
21
Clinicopathological features of patients with concomitant intraductal papillary mucinous neoplasm of the pancreas and pancreatic endocrine neoplasm. ( 17124434 )
2006
22
Pancreatic endocrine neoplasm can mimic serous cystadenoma. ( 16110124 )
2005
23
Synchronous primary pancreatic endocrine neoplasm and adrenal pheochromocytoma diagnosed by EUS-guided FNA. ( 14722570 )
2004
24
Cutaneous tumors in patients with multiple endocrine neoplasm type 1 (MEN1) and gastrinomas: prospective study of frequency and development of criteria with high sensitivity and specificity for MEN1. ( 15531478 )
2004
25
A case of exocrine-endocrine neoplasm of the pancreas in a patient with ulcerative colitis with literature review. ( 17415836 )
2004
26
[Study of RET protooncogene in multiple endocrine neoplasm 2A and in familial medullary thyroid carcinoma. Clinical pathological findings in asymptomatic carriers]. ( 12673960 )
2003
27
Ghrelin expression in islet cell tumors: augmented expression of ghrelin in a case of glucagonoma with multiple endocrine neoplasm type I. ( 12414844 )
2002
28
Determination of allelic deletion of multiple endocrine neoplasm type 1 (MEN1) gene in acute myeloid leukemia (AML) by application of FISH-TSA technique. ( 12210500 )
2002
29
Four cases of mucosal neuroma syndrome: multiple endocrine neoplasm 2B or not 2B? ( 9435410 )
1998
30
Antitumor effect of a neutralizing antibody to vascular endothelial growth factor on liver metastasis of endocrine neoplasm. ( 9818029 )
1998
31
Endocrine neoplasm arising from duodenal heterotopic pancreas: a case report. ( 9283871 )
1997
32
Endocrine gland cancer. ( 8001005 )
1995
33
Multiple endocrine neoplasm, type 1. Gastrinomas, pancreatic neoplasms, microcarcinoids, the Zollinger-Ellison syndrome, lymph nodes, and hepatic metastases. ( 8105768 )
1993
34
Thyroid cancer: a lethal endocrine neoplasm. ( 2058861 )
1991
35
Solid-cystic tumour of the pancreas. An endocrine neoplasm? ( 2110701 )
1990
36
Medullary thyroid carcinoma in multiple endocrine neoplasm type II syndromes. ( 2864758 )
1985
37
Multiple endocrine neoplasm. Exposure to radiation? ( 6132550 )
1983
38
Mediastinal endocrine neoplasm, of probable thymic origin, related to carcinoid tumor. Clinicopathologic study of 8 cases. ( 4111691 )
1972
39
Mediastinal endocrine neoplasm in patients with multiple endocrine adenomatosis. A previously unrecognized association. ( 4401563 )
1972

Variations for Endocrine Gland Cancer

Expression for Endocrine Gland Cancer

Search GEO for disease gene expression data for Endocrine Gland Cancer.

Pathways for Endocrine Gland Cancer

Pathways related to Endocrine Gland Cancer according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 12.53 BRCA2 GNAS MLH1 RET TP53
2
Show member pathways
12.25 BRCA1 BRCA2 GNAS KDR TP53
3
Show member pathways
12.22 BRCA1 BRCA2 HIST2H2AA3 MLH1
4 11.58 BRCA1 BRCA2 MLH1
5
Show member pathways
11.46 BRCA1 BRCA2 TP53
6 11.36 BRCA1 MLH1 TP53
7 11.09 GCG GNAS IAPP VIP
8 10.86 BRCA1 BRCA2 MLH1 TP53
9 10 GAST VIP

GO Terms for Endocrine Gland Cancer

Cellular components related to Endocrine Gland Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.36 AFP CHGA GAST GCG GNAS IAPP
2 lateral element GO:0000800 8.96 BRCA1 BRCA2

Biological processes related to Endocrine Gland Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.67 GCG KDR TP53 VIP
2 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.5 BRCA1 BRCA2 MLH1
3 adenylate cyclase-activating G protein-coupled receptor signaling pathway GO:0007189 9.46 GCG GNAS IAPP VIP
4 regulation of signaling receptor activity GO:0010469 9.43 GAST GCG IAPP SST TG VIP
5 chordate embryonic development GO:0043009 9.26 BRCA1 BRCA2
6 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 8.8 BRCA1 BRCA2 TP53

Molecular functions related to Endocrine Gland Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.5 BRCA1 BRCA2 GCG IAPP KDR SYP
2 hormone activity GO:0005179 9.1 GAST GCG IAPP SST TG VIP

Sources for Endocrine Gland Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....